Application of chemistry-based functional proteomics to screening for novel drug targets

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 5, 2010, Pages 414-421

  Yuan, Kefei ^a   Lei, Yunlong ^a   Huang, Canhua ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Activity based probe; Drug target; Mass spectrometry; Proteomics

Indexed keywords

BIOTIN; FATTY ACID AMIDASE INHIBITOR; FATTY ACYL TRIFLUOROMETHYL KETONE; FLUOROMETHYLPHENOL; HALOACETOPHENONE; METALLOPROTEINASE; OLEOYL TRIFLUOROMETHYL KETONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOTYROSINE; RHODAMINE; SERINE DEHYDRATASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FUNCTIONAL PROTEOMICS; GENE SEQUENCE; GENOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PROTEINS; PROTEOMICS;

EID: 77955761883     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710791292976     Document Type: Review

References (85)

1. Drews, J. Drug discovery: a historical perspective. Science, 2000, 287, 1960-1964.
2. Cockett, M.; Dracopoli, N.; Sigal, E. Applied genomics: integration of the technology within pharmaceutical research and development. Curr. Opin. Biotech., 2000, 11, 602-609.
3. Jeffery, D. A.; Bogyo, M. Chemical proteomics and its application to drug discovery. Curr. Opin. Biotech., 2003, 14, 87-95.
4. Myers, S.; Baker, A. Drug discovery - an operating model for a new era. Nat. Biotechnol., 2001, 19, 727-730.
5. Saghatelian, A.; Jessani, N.; Joseph, A.; Humphrey, M.; Cravatt, B. F. Activity-based probes for the proteomic profiling of metalloproteases. PNAS, 2004, 101, 10000-10005.
6. Paulick, M. G.; Bogyo, M. Application of activity-based probes to the study of enzymes involved in cancer progression. Curr. Opin. Genet. Dev., 2008, 18, 97-106.
7. Bantscheff, M.; Scholten, A.; Heck, A. J. Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov. Today, 2009, 585, 1-9.
8. Hanash, S. Disease proteomics. Nature, 2003, 422, 226-232.
9. Lasonder, E.; Ishihama, Y.; Anderson, J. S.; Vermunt A. M.; Mann, M. Analysis of the Plasmodium falciparumproteome by highaccuracy mass spectrometry. Nature, 2002, 419, 537-542.
10. Florens, L.; Washburn, M. P.; Raine, J.; Anthony, R. M.; Carruci, D. J. A proteomic view of the Plasmodium falciparumlife cycle. Nature, 2002, 419, 520-526.
11. Liotta, L; Espina, V.; Mehta, A. I. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell., 2003, 3, 317-325.
12. Lal, S. P.; Christopherson, R. I.; Remedios, C. G. Antibody arrays:an embryonic but rapidly growing technology. Drug Discov. Today, 2002, 7, 143-149.
13. Zhu, H.; Snyder, M. Protein chip technology. Curr. Opin. Chem. Biol., 2003, 7, 55-63.
14. MacBeath, G.; Schreiber, S. L. Printing proteins as microarrays for high-throughput function determination. Science, 2000, 289, 1760-1763.
15. Humphery-Smith, I.; Wischerhoff, E.; Hashimoto, R. Protein arrays for assessment of target selectivity. Drug Discov. World. 2002, 4, 17-27.
16. Newman, D. J.; Cragg, G..vaM. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
17. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
18. Wong, C. C.; Cheng, K.; He, Q.; Chen F. Unraveling the molecular targets of natural products: Insights from genomic and proteomic analyses. Proteomics Clin. Appl., 2008, 2, 338-354.
19. Schmitz, F. J.; Gunasekera, S. P.; Lakshmi, V.; Tillekeratne, L. M. Marine natural-products - pyrrololactams fromseveral sponges, J. Nat. Prod., 1985, 48, 47-53.
20. Walsh, D. P.; Chang, Y. T.; Chemical genetics. Chem. Rev., 2006, 106, 2476-2530.
21. Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol., 2000, 7, 51-63.
22. Chaurand, P.; Stoeckli, M.; Caprioli, R. M. Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Anal. Chem., 1999, 71, 5263-5270. (Pubitemid 129563241)
23. MacBeath, G.. Protein microarrays and proteomics. Nat. Genet., 2002, 32, 526-532.
24. Lee, A. Y.; Paweletz, C. P.; Pollock, R. M.; Settlage, R. E.; Hendrickson R. C. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.. J. Proteome Res., 2008, 7, 5177-5186.
25. Liang, X.; Hajivandi, M.; Veach, Darren.; Pope, R. M. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics, 2006, 6, 4554-4564.
26. Song, D.; Chaerkady, R.; Tan, AC. Antitumor activity and molecular effects of novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther., 2008, 7, 3275-3284.
27. Liu, R.; Li, Z. J.; Bai, S. J.; Zhang, H. Y.; Tang, M. H.; Lei, Y. L.; Chen, L. J.; Liang, S. F.; Zhao, Y. L.; Wei, Y. Q.; Huang, C. H. Mechanism of cancer cell adaptation to metabolic stress proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol. Cell. Proteomics, 2009, 8, 70-85.
28. Adam, G. C.; Sorensen, E. J. Cravatt, B. F. Chemical strategies for functional proteomics. Mol. Cell. Proteomics, 2002, 1, 781-790.
29. Jessani, N; Niessen, S.; Wei B. Q.; Nicolau, M.; Cravatt, B. F. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods, 2005, 2, 691-697.
30. Berger, A. B.; Vitorino, P. M.; Bogyo, M. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogen, 2004, 4, 371-381.
31. Greenbaum, D.; Medzihradszky, K. F.; Burlingame, A.; Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol., 2000, 7, 569-581.
32. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-730.
33. Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Activity-based protein profiling: The serine hydrolases. PNAS, 1999, 96, 14694-14699.
34. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Holt, R. A. The sequence of the human genome. Science, 2001, 291, 1304-1351.
35. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; FitzHugh, W. Initial sequencing and analysis of the human genome. Nature, 2001, 409, 860-921.
36. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem., 2000, 43, 305-341.
37. Heck, A. M.; Yanovski, J. A.; Calis, K. A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 2000, 20, 270-279.
38. Deadman, J. Proteinase inhibitors and activators: strategic targets for therapeutic intervention. J. Pept. Sci., 2000, 6, 421-431.
39. Kidd, D.; Liu, Y.; Cravatt, B. F. Profiling serine hydrolase activities in complex proteomes. Biochemistry, 2001, 40, 4005-4015.
40. Patterson, J. E.; Ollman, I. R.; Cravatt, B. F.; Boger, D. L.; Lerner, R. A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J. Am. Chem. Soc, 1996, 118, 5938-5945.
41. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Cravatt, B. F. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition. Bioorg. Med. Chem. Lett., 1999, 9, 265-270.
42. Ueda, N.; Kurahashi, Y.; Yamamoto, S.; Tokunaga, T. J. Partial purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and Synthesizing Anasndamide. Biol. Chem., 1995, 270, 23823-23827.
43. Maurelli, S.; Bisogno, T.; De Petrocellis, L.; Di Luccia, A.; Di Marzo, V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett., 1995, 377, 82-86.
44. Cohen, P. Protein kinases - the major drug targets of the twentyfirst century? Nat. Rev. Drug. Discov., 2002, 1, 309-315.
45. McCluskey, A.; Sim, A. T.; Sakoff, J. A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem., 2002, 45, 1151-1175.
46. Colman, RF. Affinity labeling of purine nucleotide sites in proteins. Annu. Rev. Biochem., 1983, 52, 67-91.
47. Wymann, M. P.; Bulgarelli-Leva, G.; Zvelebil, M. J.; Pirola, L.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol, 1996, 16, 1722-1733.
48. Garcia-Echeverria, C; Traxler, P.; Evans, D. B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev., 2000, 20, 28-57.
49. Mustelin, T.; Feng, G. S.; Bottini, N.; Alonso, A.; Huynh H. Protein tyrosine phosphatases. Front Bio sci., 2002, 7, 85-142.
50. Arabcai, G.; Guo, X.; Beeke, K. D.; Coggeshall, K. M.; Pei, D. α-haloacetophenones derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J. Am. Chem. Soc, 1999, 121, 5085-5086.
51. Denu, J. M.; Dixon, J. E. Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr. Opin. Chem. Biol, 1998, 2, 633-641.
52. Kumar, S.; Zhou, B.; Liang, F.; Wang, W. Q.; Zhang, Z. Z. Activitybased probes for protein tyrosine phosphatases. PNAS, 2004, 101, 7943-7948.
53. Shackelford, J.; Pagano, J. S. Tumor viruses and cell signaling pathways: deubiquintination versus ubiquitination. Mol. Cell. Biol, 2004, 24, 5089-5093.
54. Niedzwiedz, W.; Patel, K. J. "Dub" bing a tumor suppressor pathway. Cancer Cell, 2005, 7, 114-115.
55. Borodovsky, A.; Ovaa, H.; Kolli, N.; Kessler, B. M. Chemistrybased functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol, 2002, 9, 1149-1159.
56. Borodovsky, A.; Ovaa, H.; Meester, W. J.; Kessler, B. M.; Overkleeft, H. S. Small-molecule inhibitors and probes for ubiquitin-and ubiquitin-like- specific proteases. Chembiochem, 2005, 6, 287-291.
57. Lam, Y. A.; Xu, W.; DeMartino, G. N.; Cohen, R. E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature, 1997, 385, 737-740.
58. Cotton, G. J.; Muir, T. W. Peptide ligation and its application to protein engineering. Chem. Biol, 1999, 6, 247-256.
59. Horst, A.; Vries-Smits, A.; Brenkman, A. B.; Burgering, B. M. FOXO4 transcriptional activity is regulated bymonoubiquitination and USP7/HAUSP. Nat. Cell. Biol, 2006, 8, 1064-1073.
60. Holowaty, M. N.; Zeghouf, M.; Wu, H.; Tellam, J.; Frappier, L. Protein profiling with epstein-barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J. Biol. Chem., 2003, 278, 29987-29994.
61. Avvakumov, G. V.; Walker, J. R.; Xue, S.; Dhe-Paganon, S. Aminoterminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J. Biol. Chem., 2006, 281, 38061-38070.
62. Wu, X.; Yen, L.; Irwin, L.; Carraway III, K. L. Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol. Cell. Biol., 2004, 24, 7748-7757.
63. Yao, T.; Song, L.; Xu, W.; Cohen, R. E. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat. Cell. Biol, 2006, 8, 994-1002.
64. Wicks, S. J.; Haros, K.; Maillard, M.; Chantry, A. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-β signalling. Oncogene, 2005, 24, 8080-8084.
65. Borodovsky, A. Kessler, B. M.; Ploegh, H. L. A novel active sitedirected probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J., 2001, 20, 5187-5196.
66. Wilson, S. M.; Bhattacharyya, B.; Rachel, R. A.; Jenkins, N. A. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet., 2002, 32, 420-425.
67. Timms, K. M.; Ansari-Lari, M. A.; Morris, W.; Brown, S. N.; Gibbs, R. A. The genomic organization of Isopeptidase T-3 (ISOT-3), a new member of the ubiquitin specific protease family (UBP). Gene, 1998, 217, 101-106.
68. Gabriel, J. M.; Lacombe, T.; Carobbio, S.; Jaton, C. Zinc is required for the catalytic activity of the human deubiquitinating isopeptidase T. Biochemistry, 2002, 41, 13755-13766.
69. Pantaleon, M.; Kanai-Azuma, M.; Mattick, J. S.; Wood, S. FAM deubiquitylating enzyme is essential for preimplantation mouse embryo development. Mech. Dev., 2001, 109, 151-160.
70. Jensen, D. E.; Proctor, M.; Marquis, S. T.; Gardner, H. P. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene, 1998, 16, 1097-1112.
71. Hua, J.; Grisafi, P.; Cheng, S.; Fink, G. R. Plant growth homeostasis is controlled by the Arabidopsis BON1 and BAP1 genes. Genes Dev, 2001, 15, 2263-2272.
72. Liu, Y; Fallon, L.; Lashuel, H. A.; Liu, Z.; Lansbury, P. T. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and parkinson's disease susceptibility. Cell, 2002, 111, 209-218.
73. Liu, Y; Lashuel, H. A.; Choi, S.; Lansbury, P. T. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol, 2003, 10, 837-846.
74. Johnston, S. C.; Larsen, C. N.; Cook, W. J.; Hill, C. P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 Å resolution. EMBO J., 1997, 16, 3787-3796.
75. Misaghi, S.; Galardy, P. J.; Meester, W. J. N.; Ovaa, H.; Gaudet D. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J. Biol. Chem., 2005, 280, 1512-1520.
76. Hemelaar, J.; Galardy, P. J.; Borodovsky, A.; Ovaa, H. Chemistrybased functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res., 2004, 3, 268-276.
77. Chong, S.; Mersha, F. B.; Comb, D. G.; Hirvonen, C. A. Singlecolumn purification of free recombinant proteins using a selfcleavable affinity tag derived from a protein splicing element. Gene, 1997, 192, 271-281.
78. Makarova, K. S.; Aravind, L.; Koonin, E. V. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci., 2000, 25, 50-52.
79. Liu, Y. C.; Lashuel, H. A.; Choi, S.; Lansury, P. T. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol., 2003, 10, 837-846.
80. Love, K. R.; Catic, A.; Schlieker, C.; Ploegh, H. L. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat. Chem. Biol., 2007, 3, 697-705.
81. Lee, W. C.; Lee, K. H. Applications of affinity chromatography in proteomics. Anal. Biochem., 2004, 324, 1-10.
82. Ficarro, S. B.; McCleland, M. L.; White, F. M. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat. Biotechnol., 2002, 20, 301-305.
83. Brehmer, D.; Godl, K.; Zech, B.; Daub, H. Proteome-wide identification of cellular targets affected by bisindolylmaleimidetype protein kinase C inhibitors. Mol. Cell. Proteomics, 2004, 3, 490-500.
84. Kruse, U.; Bantscheff, M.; Drewes, G.; Hopf, C. Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol. Cell. Proteomics, 2008, 7, 1887-1901.
85. Saxena, C.; Zhen, E.; Higgs, R. E.; Hale, J. E. An immuno-chemoproteomics method for drug target deconvolution. J. Proteome Res., 2008, 7, 3490-3497.